Course Description
- Review the FDAs position on the incorporation of patients in drug clinical trials;
- Describe comparative effectiveness research methodology that include the patient perspective;
- Discuss the FDAs paradigm shift to include patient involvement in drug development.
Presentation includes information on:
Provide an overview on the FDAs shift in reviewing drug development, primary end points and drug indications in Phase II-IV randomized clinical trials.
Review the role of comparative effectiveness research and its methodology that includes patient participation
Identify how the patient’s involvement in drug trials and study design impact drug delivery, package insert and introduction to market
Virna Dapic, PhD
Course curriculum
-
1
View Class by Dr. Dapic Taught at the Multiple Chronic Conditions Policy Conference - March 2015
-
Dr. Dapic's Class at the 2015 Multiple Chronic Conditions Policy Conference Taught in Savannah, GA
-